Isis Pharmaceuticals


Company Update (NASDAQ:ISIS): ISIS Pharmaceuticals, Inc. Earns $2.8M for Advancing ISIS-DMPK-2.5 Rx in Patients with Myotonic Dystrophy Type I

ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) announced that it has earned a $2.

Stock Update (NASDAQ:ISIS): ISIS Pharmaceuticals, Inc. Reports Data from ISIS-SMN Rx in Children with Spinal Muscular Atrophy

ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) provided an update on children with spinal muscular atrophy (SMA) who have completed the open-label, Phase 2 multiple-dose study of ISIS-SMNRx …

Company Update (NASDAQ:ISIS): Isis Pharmaceuticals, Inc. Reports Data from ISIS-SMN Rx Phase 2 Study in Infants with Spinal Muscular Atrophy

Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) provided an update on its ongoing open-label Phase 2 clinical study of ISIS-SMNRx in infants with Type I spinal …

Stock Update (NASDAQ:ISIS): ISIS Pharmaceuticals, Inc.’s License Agreement with Bayer for ISIS-FXI Rx Receives Hart-Scott-Rodino Approval

ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) announced that its license agreement with Bayer HealthCare (Bayer) to develop and commercialize ISIS-FXIRx has received clearance under the Hart-Scott-Rodino …

Stock Update (NASDAQ:ISIS): ISIS Pharmaceuticals, Inc Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis

ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) has entered into an exclusive license agreement with Bayer HealthCare (Bayer) to develop and commercialize ISIS-FXIRx for the prevention …

Stock Update (NASDAQ:ISIS): Isis Pharmaceuticals Earns $15 Million From GSK for Advancing ISIS-TTR Rx

Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) announced that it has earned a $15 million milestone payment from GSK related to advancing the Phase 2/3 study of …

ISIS Pharmaceuticals Reports ISIS-PKK Positive Phase 1 Data In Prekallikrein Levels

Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) announced positive results from a Phase 1 study with ISIS-PKKRx.

Stock Update (NASDAQ:ISIS): Isis Pharmaceuticals Earns $7M for Advancing ISIS-SMN Rx in Children With Spinal Muscular Atrophy

Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) announced today that it has earned a $7 million milestone payment from Biogen Idec related to the advancement of …

Isis Pharmaceuticals Announces Collaboration With Janssen to Discover and Develop RNA-Targeted Therapeutics for Autoimmune Diseases in the GI Tract

Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) today announced that the company has entered into a global collaboration with Janssen Biotech, Inc.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts